Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

Data ReadoutpositiveontunisertibPositive

AI Analysis

Summary

Agomab reported positive topline results from the 48-week open-label extension study of ontunisertib in fibrostenosing Crohn's disease patients. The Phase 2a STENOVA trial demonstrated favorable outcomes in this patient population.

Clinical Trial Data

Phase

Outcome Details

Positive topline data from 48-week open-label extension portion of Phase 2a STENOVA trial

Importance:6/10

Sentiment:

0.75

Phase 2 dataontunisertibCrohn's diseaseopen-label extension

Read the original article

Published by GlobeNewswire Clinical Studies on October 1, 2026 10:30 AM

Read Original